Elena B Pasquale

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4826034/publications.pdf

Version: 2024-02-01

74 papers	8,113 citations	87888 38 h-index	82547 72 g-index
80 all docs	80 docs citations	80 times ranked	7720 citing authors

#	Article	IF	Citations
1	Eph-Ephrin Bidirectional Signaling in Physiology and Disease. Cell, 2008, 133, 38-52.	28.9	1,121
2	Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nature Reviews Cancer, 2010, 10, 165-180.	28.4	1,050
3	Eph receptor signalling casts a wide net on cell behaviour. Nature Reviews Molecular Cell Biology, 2005, 6, 462-475.	37.0	933
4	Control of hippocampal dendritic spine morphology through ephrin-A3/EphA4 signaling. Nature Neuroscience, 2003, 6, 153-160.	14.8	466
5	The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene, 2000, 19, 6043-6052.	5.9	336
6	Eph Receptor Signaling and Ephrins. Cold Spring Harbor Perspectives in Biology, 2013, 5, a009159-a009159.	5.5	325
7	Neuron-glia communication via EphA4/ephrin-A3 modulates LTP through glial glutamate transport. Nature Neuroscience, 2009, 12, 1285-1292.	14.8	258
8	Eph Receptors and Ephrins: Therapeutic Opportunities. Annual Review of Pharmacology and Toxicology, 2015, 55, 465-487.	9.4	242
9	Glial ephrin-A3 regulates hippocampal dendritic spine morphology and glutamate transport. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12524-12529.	7.1	181
10	An Ephrin Mimetic Peptide That Selectively Targets the EphA2 Receptor. Journal of Biological Chemistry, 2002, 277, 46974-46979.	3.4	179
11	The EphA2 Receptor Drives Self-Renewal and Tumorigenicity in Stem-like Tumor-Propagating Cells from Human Glioblastomas. Cancer Cell, 2012, 22, 765-780.	16.8	179
12	Ephâ€“ephrin promiscuity is now crystal clear. Nature Neuroscience, 2004, 7, 417-418.	14.8	140
13	Eph receptors in the adult brain. Current Opinion in Neurobiology, 2004, 14, 288-296.	4.2	138
14	Matrix Rigidity Controls Epithelial-Mesenchymal Plasticity and Tumor Metastasis via a Mechanoresponsive EPHA2/LYN Complex. Developmental Cell, 2020, 54, 302-316.e7.	7.0	128
15	EphB Receptor-binding Peptides Identified by Phage Display Enable Design of an Antagonist with Ephrin-like Affinity. Journal of Biological Chemistry, 2005, 280, 17301-17311.	3.4	124
16	Small Molecules Can Selectively Inhibit Ephrin Binding to the EphA4 and EphA2 Receptors. Journal of Biological Chemistry, 2008, 283, 29461-29472.	3.4	123
17	Replacing two conserved tyrosines of the EphB2 receptor with glutamic acid prevents binding of SH2 domains without abrogating kinase activity and biological responses. Oncogene, 2000, 19, 177-187.	5.9	108
18	Complex formation between EphB2 and Src requires phosphorylation of tyrosine 611 in the EphB2 juxtamembrane region. Oncogene, 1998, 16, 2657-2670.	5.9	107

#	Article	IF	Citations
19	Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells. Cellular Signalling, 2011, 23, 201-212.	3.6	95
20	Targeting the EphA4 receptor in the nervous system with biologically active peptides. Molecular and Cellular Neurosciences, 2003, 24, 1000-1011.	2.2	93
21	Inhibition of Integrin-mediated Cell Adhesion but Not Directional Cell Migration Requires Catalytic Activity of EphB3 Receptor Tyrosine Kinase. Journal of Biological Chemistry, 2005, 280, 923-932.	3.4	92
22	Targeting Eph receptors with peptides and small molecules: Progress and challenges. Seminars in Cell and Developmental Biology, 2012, 23, 51-57.	5.0	89
23	Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapyâ€“Mediated Metastatic Melanoma Phenotype. Cancer Discovery, 2015, 5, 264-273.	9.4	82
24	Novel Targeted System To Deliver Chemotherapeutic Drugs to EphA2-Expressing Cancer Cells. Journal of Medicinal Chemistry, 2012, 55, 2427-2436.	6.4	79
25	EphA4 Activation of c-Abl Mediates Synaptic Loss and LTP Blockade Caused by Amyloid-Î² Oligomers. PLoS ONE, 2014, 9, e92309.	2.5	75
26	The EphA4 Receptor Regulates Neuronal Morphology through SPAR-Mediated Inactivation of Rap GTPases. Journal of Neuroscience, 2007, 27, 14205-14215.	3.6	74
27	Structure of ERK2 bound to PEA-15 reveals a mechanism for rapid release of activated MAPK. Nature Communications, 2013, 4, 1681.	12.8	69
28	The EphA2 receptor is activated through induction of distinct, ligand-dependent oligomeric structures. Communications Biology, 2018, 1, 15.	4.4	62
29	Protein kinase A can block EphA2 receptorâ€“mediated cell repulsion by increasing EphA2 S897 phosphorylation. Molecular Biology of the Cell, 2016, 27, 2757-2770.	2.1	59
30	The Eph family: a multitude of receptors that mediate cell recognition signals. Cell and Tissue Research, 1997, 290, 217-226.	2.9	58
31	EphA2 Receptor Unliganded Dimers Suppress EphA2 Pro-tumorigenic Signaling. Journal of Biological Chemistry, 2015, 290, 27271-27279.	3.4	58
32	Ephrin-A6, a New Ligand for EphA Receptors in the Developing Visual System. Developmental Biology, 2001, 230, 74-88.	2.0	56
33	Structureâ^'Activity Relationship Analysis of Peptides Targeting the EphA2 Receptor. Biochemistry, 2010, 49, 6687-6695.	2.5	56
34	Profiling Eph receptor expression in cells and tissues. Cell Adhesion and Migration, 2012, 6, 102-156.	2.7	54
35	Targeted Delivery of Paclitaxel to EphA2-Expressing Cancer Cells. Clinical Cancer Research, 2013, 19, 128-137.	7.0	53
36	Targeting the Eph System with Peptides and Peptide Conjugates. Current Drug Targets, 2015, 16, 1031-1047.	2.1	48

#	Article	IF	Citations
37	Attenuation of Eph Receptor Kinase Activation in Cancer Cells by Coexpressed Ephrin Ligands. PLoS ONE, 2013, 8, e81445.	2.5	47
38	Unliganded EphA3 dimerization promoted by the SAM domain. Biochemical Journal, 2015, 471, 101-109.	3.7	45
39	The SAM domain inhibits EphA2 interactions in the plasma membrane. Biochimica Et Biophysica Acta - Molecular Cell Research, 2017, 1864, 31-38.	4.1	43
40	Development and Structural Analysis of a Nanomolar Cyclic Peptide Antagonist for the EphA4 Receptor. ACS Chemical Biology, 2014, 9, 2787-2795.	3.4	40
41	Design and Synthesis of Potent Bivalent Peptide Agonists Targeting the EphA2 Receptor. ACS Medicinal Chemistry Letters, 2013, 4, 344-348.	2.8	37
42	Inhibition of EphB4â€“Ephrin-B2 Signaling Reprograms the Tumor Immune Microenvironment in Head and Neck Cancers. Cancer Research, 2019, 79, 2722-2735.	0.9	36
43	PEGylation Potentiates the Effectiveness of an Antagonistic Peptide That Targets the EphB4 Receptor with Nanomolar Affinity. PLoS ONE, 2011, 6, e28611.	2.5	36
44	SORLA attenuates EphA4 signaling and amyloid Î²â€“induced neurodegeneration. Journal of Experimental Medicine, 2017, 214, 3669-3685.	8.5	35
45	Design, Synthesis and Bioevaluation of an EphA2 Receptorâ€Based Targeted Delivery System. ChemMedChem, 2014, 9, 1403-1412.	3.2	31
46	Structure-Guided Strategy for the Development of Potent Bivalent ERK Inhibitors. ACS Medicinal Chemistry Letters, 2017, 8, 726-731.	2.8	31
47	Engineering nanomolar peptide ligands that differentially modulate EphA2 receptor signaling. Journal of Biological Chemistry, 2019, 294, 8791-8805.	3.4	31
48	Association of the Breast Cancer Antiestrogen Resistance Protein 1 (BCAR1) and BCAR3 Scaffolding Proteins in Cell Signaling and Antiestrogen Resistance. Journal of Biological Chemistry, 2014, 289, 10431-10444.	3.4	29
49	A small peptide promotes EphA2 kinase-dependent signaling by stabilizing EphA2 dimers. Biochimica Et Biophysica Acta - General Subjects, 2016, 1860, 1922-1928.	2.4	28
50	Ligand bias in receptor tyrosine kinase signaling. Journal of Biological Chemistry, 2020, 295, 18494-18507.	3.4	28
51	Knockdown of EphB1 receptor decreases medulloblastoma cell growth and migration and increases cellular radiosensitization. Oncotarget, 2015, 6, 8929-8946.	1.8	25
52	Noncanonical EphA2 Signaling Is a Driver of Tumor-Endothelial Cell Interactions and Metastatic Dissemination in BRAF Inhibitorâ€'Resistant Melanoma. Journal of Investigative Dermatology, 2021, 141, 840-851.e4.	0.7	19
53	Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas. Scientific Reports, 2016, 6, 38792.	3.3	18
54	Exosomes expand the sphere of influence of Eph receptors and ephrins. Journal of Cell Biology, 2016, 214, 5-7.	5.2	18

#	Article	IF	Citations
55	Soluble SORLA Enhances Neurite Outgrowth and Regeneration through Activation of the EGF Receptor/ERK Signaling Axis. Journal of Neuroscience, 2020, 40, 5908-5921.	3.6	17
56	A cellular target engagement assay for the characterization of SHP2 (PTPN11) phosphatase inhibitors. Journal of Biological Chemistry, 2020, 295, 2601-2613.	3.4	16
57	Modifications of a Nanomolar Cyclic Peptide Antagonist for the EphA4 Receptor To Achieve High Plasma Stability. ACS Medicinal Chemistry Letters, 2016, 7, 841-846.	2.8	15
58	Evaluation of EphA2 and EphB4 as Targets for Image-Guided Colorectal Cancer Surgery. International Journal of Molecular Sciences, 2017, 18, 307.	4.1	14
59	Genetically Encoded FRET Biosensor for Visualizing EphA4 Activity in Different Compartments of the Plasma Membrane. ACS Sensors, 2019, 4, 294-300.	7.8	11
60	Regulation of the EphA2 receptor intracellular region by phosphomimetic negative charges in the kinase-SAM linker. Nature Communications, 2021, 12, 7047.	12.8	11
61	A cancer mutation promotes EphA4 oligomerization and signaling by altering the conformation of the SAM domain. Journal of Biological Chemistry, 2021, 297, 100876.	3.4	9
62	EphB4 and ephrinB2 act in opposition in the head and neck tumor microenvironment. Nature Communications, 2022, 13, .	12.8	9
63	Environmental enrichment during the chronic phase after experimental stroke promotes functional recovery without synergistic effects of EphA4 targeted therapy. Human Molecular Genetics, 2020, 29, 605-617.	2.9	8
64	Ligands with different dimeric configurations potently activate the EphA2 receptor and reveal its potential for biased signaling. IScience, 2022, 25, 103870.	4.1	8
65	Discovery of novel furanylbenzamide inhibitors that target oncogenic tyrosine phosphatase SHP2 in leukemia cells. Journal of Biological Chemistry, 2022, 298, 101477.	3.4	6
66	Protein kinase C phosphorylates the EphA2 receptor on serine 892 in the regulatory linker connecting the kinase and SAM domains. Cellular Signalling, 2020, 73, 109668.	3.6	5
67	Phosphorylation of guanosine monophosphate reductase triggers a GTP-dependent switch from pro- to anti-oncogenic function of EPHA4. Cell Chemical Biology, 2022, 29, 970-984.e6.	5.2	4
68	Regional expression and ultrastructural localization of EphA7 in the hippocampus and cerebellum of adult rat. Journal of Comparative Neurology, 2016, 524, 2462-2478.	1.6	3
69	Journal club. Nature, 2009, 461, 149-149.	27.8	2
70	Eph receptors and ephrins engage in cellular cannibalism. Journal of Cell Biology, 2019, 218, 3168-3170.	5.2	2
71	EPH Receptors and Ephrins. , 2007, , 27-66.		1
72	Direct Quantification of Ligandâ€Induced Lipid and Protein Microdomains with Distinctive Signaling Properties**. ChemSystemsChem, 2022, 4, .	2.6	1

#	Article	IF	Citations
73	Structural and Binding Study on the Interaction of Small Molecule Antagonists with the EphA4 Receptor. FASEB Journal, 2009, 23, LB297.	0.5	0
74	Role of the EphA4 and EphA7 genes in mediating the growth and aggressiveness of medulloblastoma tumors in the Smo/Smo medulloblastoma mouse model.. Journal of Clinical Oncology, 2014, 32, e22137-e22137.	1.6	0